Latest news with #AndrewMokCFA
Business Insider
19-07-2025
- Business
- Business Insider
TD Cowen Sticks to Its Hold Rating for Humana (HUM)
TD Cowen analyst Ryan Langston reiterated a Hold rating on Humana today and set a price target of $268.00. The company's shares closed today at $220.41. Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week. Langston covers the Healthcare sector, focusing on stocks such as UnitedHealth, Humana, and Astrana Health. According to TipRanks, Langston has an average return of -15.2% and a 20.00% success rate on recommended stocks. In addition to TD Cowen, Humana also received a Hold from Barclays's Andrew Mok CFA in a report issued today. However, on the same day, Mizuho Securities maintained a Buy rating on Humana (NYSE: HUM).
Business Insider
05-06-2025
- Business
- Business Insider
Leerink Partners Sticks to Its Buy Rating for HCA Healthcare (HCA)
Leerink Partners analyst Whit Mayo maintained a Buy rating on HCA Healthcare (HCA – Research Report) yesterday and set a price target of $420.00. The company's shares closed yesterday at $381.66. Confident Investing Starts Here: Mayo covers the Healthcare sector, focusing on stocks such as Humana, Pediatrix Medical Group, and Tenet Healthcare. According to TipRanks, Mayo has an average return of 2.9% and a 49.75% success rate on recommended stocks. In addition to Leerink Partners, HCA Healthcare also received a Buy from Barclays's Andrew Mok CFA in a report issued on June 3. However, on May 29, Wells Fargo upgraded HCA Healthcare (NYSE: HCA) to a Hold. Based on HCA Healthcare's latest earnings release for the quarter ending March 31, the company reported a quarterly revenue of $18.32 billion and a net profit of $1.61 billion. In comparison, last year the company earned a revenue of $17.34 billion and had a net profit of $1.59 billion Based on the recent corporate insider activity of 59 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of HCA in relation to earlier this year. Last month, Jon Foster, the EVP & COO of HCA sold 15,698.00 shares for a total of $5,797,585.36.
Yahoo
27-05-2025
- Business
- Yahoo
Barclays Maintains Equal Weight Rating on Surgery Partners (SGRY), Cuts PT
On May 27, Barclays analyst Andrew Mok CFA maintained an Equal Weight rating on Surgery Partners, Inc. (NASDAQ:SGRY) and reduced the price target to $24 from $25. The rating update came after Surgery Partners, Inc. (NASDAQ:SGRY) reported mixed fiscal Q1 2025 results on May 12. The analyst told investors in a research update that while the company's performance for the quarter showed effective physician recruitment and strong demand, factors such as rising unit costs and slower pricing growth demand a cautious approach. A surgeon wearing gloves and a mask, performing a procedure in a well-equipped surgical facility. Surgery Partners, Inc. (NASDAQ:SGRY) added around 150 new physicians to its facilities in fiscal Q1 2025, most of whom management expects to become partners eventually. Revenue for the quarter rose 8.2%, while adjusted EBITDA grew around 7%, supported by strong organic results. This included strong demand and same-facility revenue growth of more than 5%. However, the company missed on earnings expectations in its fiscal Q1 2025 results, with reported EPS of $0.04 falling below the expected $0.08. Net loss attributed to the company in the quarter came up to $37.7 million. These contrasting trends led the analyst to slash the price target for Surgery Partners, Inc. (NASDAQ:SGRY). Surgery Partners, Inc. (NASDAQ:SGRY) is a healthcare services company that provides surgical and related ancillary care solutions. Its operations are divided into the Surgical Facility Services, Ancillary Services, and Optical Services business segments. While we acknowledge the potential of SGRY as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than SGRY and that has 100x upside potential, check out our report about the . READ NEXT: and . Disclosure: None.
Business Insider
05-05-2025
- Business
- Business Insider
Barclays Remains a Buy on Cigna (CI)
Barclays analyst Andrew Mok CFA maintained a Buy rating on Cigna (CI – Research Report) on May 2 and set a price target of $382.00. The company's shares closed last Friday at $334.75. Protect Your Portfolio Against Market Uncertainty Discover companies with rock-solid fundamentals in TipRanks' Smart Value Newsletter. Receive undervalued stocks, resilient to market uncertainty, delivered straight to your inbox. According to TipRanks, Mok CFA is an analyst with an average return of -10.9% and a 37.35% success rate. Mok CFA covers the Healthcare sector, focusing on stocks such as Humana, UnitedHealth, and Centene. The word on The Street in general, suggests a Strong Buy analyst consensus rating for Cigna with a $370.25 average price target. The company has a one-year high of $370.83 and a one-year low of $262.03. Currently, Cigna has an average volume of 1.8M.
Business Insider
28-04-2025
- Business
- Business Insider
Centene (CNC) Gets a Buy from Barclays
Barclays analyst Andrew Mok CFA maintained a Buy rating on Centene (CNC – Research Report) on April 25 and set a price target of $84.00. The company's shares closed last Friday at $57.69. Stay Ahead of the Market: Discover outperforming stocks and invest smarter with Top Smart Score Stocks. Filter, analyze, and streamline your search for investment opportunities using Tipranks' Stock Screener. According to TipRanks, Mok CFA is an analyst with an average return of -10.9% and a 37.35% success rate. Mok CFA covers the Healthcare sector, focusing on stocks such as UnitedHealth, Centene, and Humana. In addition to Barclays, Centene also received a Buy from Wells Fargo's Stephen Baxter in a report issued on April 25. However, on the same day, Bank of America Securities maintained a Hold rating on Centene (NYSE: CNC). Based on Centene's latest earnings release for the quarter ending March 31, the company reported a quarterly revenue of $46.62 billion and a net profit of $1.31 billion. In comparison, last year the company earned a revenue of $40.41 billion and had a net profit of $1.16 billion
